Key result
Adjunctive corticosteroids fail to reduce mortality in tuberculous pericarditis.
Why the study?
The American Thoracic Society and CDC/IDSA recently revised recommendations against routine adjunctive corticosteroids in TB pericarditis based on new evidence.
Does the routine addition of oral corticosteroids to standard anti-tuberculosis treatment reduce mortality in patients with TB pericarditis?
Meta-Analysis
Does the routine addition of oral corticosteroids to standard anti-tuberculosis treatment reduce mortality in patients with TB pericarditis?
Relative Risk: 0.66 (95% CI 0.35–1.27)
p-value: p=NS
Routine addition of oral corticosteroids to standard anti-tuberculosis treatment does not reduce mortality among patients with TB pericarditis, supporting recent guideline changes against their routine use.
No takes yet. Share an insight, caveat, or question.
No mortality benefit with adjunctive corticosteroids in TB pericarditis; confirms guideline reversal and strengthens evidence against routine use.
George et al. (2018) conducted a meta-analysis in Tuberculous pericarditis. Adjunctive corticosteroids vs. Standard anti-tuberculosis treatment alone was evaluated on Mortality (RR 0.66, 95% CI 0.35-1.27, p=NS). Adjunctive corticosteroids added to standard anti-tuberculosis treatment did not significantly reduce mortality among patients with tuberculous pericarditis (RR 0.66; 95% CI 0.35-1.27).